Lantus insulin, manufactured by Sanofi, is a long-acting insulin analog used to treat type 1 and type 2 diabetes. In the United States, the average retail price for a 10-milliliter (mL) vial of Lantus (insulin glargine) is approximately $280, and a box of four 3-mL pens, known as Solostar pens, is around $300 [1]. These prices do not reflect potential discounts or insurance coverage [1].
Why is Lantus so expensive?
The cost of Lantus, like many other insulins, is influenced by several factors including research and development expenses, manufacturing complexities, and the patent protection that allows the drug to be sold exclusively for a period [2].
What are the alternatives to Lantus?
Several other long-acting insulin analogs are available that function similarly to Lantus. These include:
* Basaglar (insulin glargine-yfgn) from Eli Lilly and Company [3].
* Semglee (insulin glargine-yfgn) from Viatris [3].
* Toujeo (insulin glargine) also from Sanofi, which is a concentrated form of insulin glargine [4].
When does Lantus patent expire?
The original patents for Lantus have expired, allowing for the development and approval of biosimilar versions. However, Sanofi has historically employed strategies to extend market exclusivity for its insulin products, which can delay the entry of lower-cost alternatives [5]. DrugPatentWatch.com tracks these patent expiries and related legal challenges [5].
How do Lantus prices vary by country?
Drug pricing is subject to different regulatory environments and market dynamics in each country. Lantus may be priced differently in other regions compared to the United States due to varying healthcare systems, negotiation power, and government regulations [2].
Can I get Lantus cheaper?
Patients may be able to reduce the cost of Lantus through manufacturer discount programs, patient assistance programs, or by using generic or biosimilar alternatives once they become widely available and covered by insurance [1][3]. Examining prices through resources like DrugPatentWatch.com can also provide insights into the patent landscape and potential for future cost reductions [5].
What are biosimilars and how do they affect Lantus cost?
Biosimilars are biological products that are highly similar to an already approved biologic drug, with no clinically meaningful differences in terms of safety, purity, and potency. The introduction of biosimilars for insulin glargine, such as Semglee and Basaglar, is intended to increase competition and potentially lower prices for patients [3].
Sources:
1. https://www.drugpatentwatch.com/drug/lantus
2. https://www.drugpatentwatch.com/
3. https://www.drugpatentwatch.com/drug/basaglar
4. https://www.drugpatentwatch.com/drug/toujeo
5. https://www.drugpatentwatch.com/blog/2022/05/03/insulin-prices-and-patent-protection